Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial (Q44193323)

30 November 2017

title

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial (English)

1 reference

30 November 2017

main subject

phase II clinical trial

0 references

1 reference

0 references

1

1 reference

30 November 2017

9

1 reference

30 November 2017

10

1 reference

30 November 2017

Jackson G Egen

22

0 references

John A Kirby

object named as

John A Kirby

23

0 references

William Jeffery Sandborn

14

object named as

William J Sandborn

1 reference

30 November 2017

8

Brian G Feagan

1 reference

30 November 2017

25

Paul Rutgeerts

1 reference

30 November 2017

Jeffrey Eastham-Anderson

19

object named as

Jeffrey Eastham-Anderson

1 reference

30 November 2017

13

Iris Dotan

1 reference

30 November 2017

12

Stefan Schreiber

1 reference

30 November 2017

7

Christopher A Lamb

1 reference

30 November 2017

15

Gaik W Tew

1 reference

30 November 2017

18

Lauri Diehl

1 reference

30 November 2017

11

Daniel C Baumgart

1 reference

30 November 2017

3

Mary Keir

1 reference

30 November 2017

Sharon O'Byrne

2

1 reference

30 November 2017

Marna Williams

4

1 reference

30 November 2017

Timothy T Lu

5

1 reference

30 November 2017

John C Mansfield

6

1 reference

30 November 2017

Diana Luca

16

1 reference

30 November 2017

Meina T Tang

17

1 reference

30 November 2017

Gert De Hertogh

20

1 reference

30 November 2017

Clementine Perrier

21

1 reference

30 November 2017

Gert van Assche

24

1 reference

30 November 2017

language of work or name

English

0 references

publication date

9 May 2014

1 reference

30 November 2017

1 reference

30 November 2017

volume

384

1 reference

30 November 2017

issue

9940

1 reference

30 November 2017

page(s)

309-318

1 reference

Inflammatory bowel disease

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Vedolizumab as induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

A reproducible grading scale for histological assessment of inflammation in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

CD103+ GALT DCs promote Foxp3+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Essential role for CD103 in the T cell-mediated regulation of experimental colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL-10 secretion and T cell homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

Regional and mucosal memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960661-9

7 January 2021

10.1016/S0140-6736(14)60661-9

Identifiers

DOI

1 reference

30 November 2017

1 reference